March 30, 2017 11:21 AM EDT

Takeda chops into Ariad staff, handing out about 180 pink slips as it revamps Boston ops

John Carroll

Editor & Founder

Christophe Weber, president and chief executive officer of Takeda Pharmaceutical Co., speaks during the 18th Nikkei Global Management Forum in Tokyo …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Takeda chops into Ariad staff, handing out about 180 pink slips as it revamps Boston ops

John Carroll

Editor & Founder

Sign up to read this article for free.

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Applied Therapeutics' rare disease drug gets a CRL

Take­da chops in­to Ari­ad staff, hand­ing out about 180 pink slips as it re­vamps Boston ops

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Takeda chops into Ariad staff, handing out about 180 pink slips as it revamps Boston ops

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Applied Therapeutics' rare disease drug gets a CRL